Aegis Capital Corp. acted as Exclusive Placement Agent on an $8 Million Private Placement for Sunshine Biopharma Inc. (NASDAQ: SBFM)

Rhea-AI Summary

Sunshine Biopharma (NASDAQ:SBFM) has successfully completed an $8 million private placement with the assistance of Aegis Capital Corp. as the exclusive placement agent. This funding will support the development of SBFM-PL4, a potential treatment for COVID-19, which has shown promise in preliminary tests against the virus. In addition to COVID-19 research, Sunshine Biopharma is developing Adva-27a, an anticancer compound effective against multidrug-resistant cancer cells. Clinical trials for Adva-27a in treating pancreatic cancer are planned at McGill University.

Positive

• Successful completion of $8 million private placement to fund COVID-19 treatment development.
• Advancement of SBFM-PL4 for COVID-19 in collaboration with the University of Georgia.
• Development of Adva-27a shows effectiveness against multidrug-resistant cancer cells.

Negative

• None.

NEW YORK, NY / ACCESSWIRE / March 15, 2022 / Aegis Capital Corp. acted as Exclusive Placement Agent on an $8 Million Private Placement for Sunshine Biopharma Inc. (NASDAQ:SBFM)

About Sunshine Biopharma, Inc.

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 5.3 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. The Company is currently advancing the development of SBFM-PL4 in collaboration with the University of Georgia, College of Pharmacy. In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

For more information, visit www.sunshinebiopharma.com

About Aegis Capital Corporation

Aegis Capital Corporation ("Aegis") has been in the wealth management and investment banking business since 1984. Aegis is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Aegis also provides research and sales and trading services to institutional investors. Aegis offers its investment representatives a conflict free service platform and is able to provide a full-range of products and services including investment banking, wealth management, insurance, retirement planning, structured products, private equity, alternatives, equity research, fixed income and special purpose vehicles.

For more information about this offering or Investment Banking Services please email Banking@aegiscap.com or call (212) 813-1010.

www.aegiscapcorp.com

Brokerage and investment advisory services are offered through Aegis Capital Corporation, a member of FINRA and SIPC. Investment and insurance products offered are not insured by the FDIC or any other federal government agency, are not deposits or other obligations of, or guaranteed by, a bank or any bank affiliate, and are subject to investment risks, including possible loss of the principal amount invested.

SOURCE: Aegis Capital Corp.

View source version on accesswire.com:
https://www.accesswire.com/693137/Aegis-Capital-Corp-acted-as-Exclusive-Placement-Agent-on-an-8-Million-Private-Placement-for-Sunshine-Biopharma-Inc-NASDAQ-SBFM

FAQ

What is the purpose of the $8 million private placement for SBFM?

The $8 million private placement will support the development of SBFM-PL4, a potential treatment for COVID-19.

What is SBFM-PL4 and its significance?

SBFM-PL4 is a lead compound developed by Sunshine Biopharma to inhibit the replication of the COVID-19 virus.

Where will the clinical trials for Adva-27a be conducted?

Clinical trials for Adva-27a are planned at McGill University's Jewish General Hospital in Montreal, Canada.

What types of cancer is Adva-27a effective against?

Adva-27a has shown effectiveness against multidrug-resistant cancer cells, including pancreatic cancer, small-cell lung cancer, breast cancer, and uterine sarcoma.